Archamps (France) and Geneva (switzerland), June 27th, 2017 at 6:00 pm CEST

Genkyotex (Euronext Paris & Brussels: FR00011790542 –, a biopharmaceutical company and the leader in NOX therapies, announced today that it has begun enrolling patients into the Company’s Phase 2 clinical trial of GKT831, its NOX1 and NOX4 enzymes inhibitor, in primary biliary cholangitis (PBC). Enrollment initiation at the first investigational center in the U.S. took place following regulatory clearance by the U.S. Food & Drug Administration and local Institutional Review Board. Dosing of the first patient is expected shortly.

Further information on :